About T3D Therapeutics
T3D Therapeutics is a company based in Durham (United States) founded in 2013 by John Didsbury.. T3D Therapeutics has raised $33.02 million across 15 funding rounds from investors including HHS, NCBiotech and National Institute on Aging. T3D Therapeutics offers products and services including T3D-959. T3D Therapeutics operates in a competitive market with competitors including Alzheon, Longeveron, Shaperon, Alchemab and Eikonizo, among others.
- Headquarter Durham, United States
- Founders John Didsbury
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name T3d Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$33.02 M (USD)
in 15 rounds
-
Latest Funding Round
$2.26 M (USD), Grant
Aug 15, 2023
-
Investors
HHS
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of T3D Therapeutics
T3D Therapeutics offers a comprehensive portfolio of products and services, including T3D-959. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets brain metabolism to treat Alzheimer's and improve cognitive function.
Unlock access to complete
Unlock access to complete
Advisor Team
8 people
Leadership Team
8 people
Product Management Team
1 people
Consultant Team
1 people
Unlock access to complete
Funding Insights of T3D Therapeutics
T3D Therapeutics has successfully raised a total of $33.02M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $2.26 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Grant — $2.3M
-
First Round
First Round
(05 Aug 2013)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Grant - T3D Therapeutics | Valuation |
investors |
|
| Sep, 2022 | Amount | Grant - T3D Therapeutics | Valuation |
investors |
|
| Sep, 2022 | Amount | Series B - T3D Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in T3D Therapeutics
T3D Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NCBiotech and National Institute on Aging. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are incubated and funded in North Carolina.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Research and information on aging are provided by this institute.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by T3D Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - T3D Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
T3d Therapeutics Comparisons
Competitors of T3D Therapeutics
T3D Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alzheon, Longeveron, Shaperon, Alchemab and Eikonizo, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for inflammatory diseases and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| domain | founded_year | HQ Location |
Brain-penetrant small molecule therapeutics for neurodegenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on T3d Therapeutics
Frequently Asked Questions about T3D Therapeutics
When was T3D Therapeutics founded?
T3D Therapeutics was founded in 2013.
Where is T3D Therapeutics located?
T3D Therapeutics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Who is the current CEO of T3D Therapeutics?
John Didsbury is the current CEO of T3D Therapeutics. They have also founded this company.
Is T3D Therapeutics a funded company?
T3D Therapeutics is a funded company, having raised a total of $33.02M across 15 funding rounds to date. The company's 1st funding round was a Series B of $6M, raised on Aug 05, 2013.
What does T3D Therapeutics do?
T3D Therapeutics was founded in 2013 and is based in Durham, United States. Operations focus on the biotechnology sector, with emphasis on creating treatments for neurodegenerative conditions. A key product, T3D-959, is designed to address multiple Alzheimers disease pathologies, such as beta-amyloid and tau pathways, along with insulin and IGF-resistance mechanisms. Development efforts target core disease triggers in this field.
Who are the top competitors of T3D Therapeutics?
T3D Therapeutics's top competitors include Alzheon, Longeveron and Alchemab.
What products or services does T3D Therapeutics offer?
T3D Therapeutics offers T3D-959.
Who are T3D Therapeutics's investors?
T3D Therapeutics has 3 investors. Key investors include HHS, NCBiotech, and National Institute on Aging.